Paclitaxel-Eluting Coronary Stents in Patients With Diabetes MellitusPooled Analysis From 5 Randomized Trials
Ajay J. Kirtane, MD, SM*,1,
Stephen G. Ellis, MD ,1,
Keith D. Dawkins, MD ,2,
Antonio Colombo, MD ,
Eberhard Grube, MD||,
Jeffrey J. Popma, MD¶,3,
Martin Fahy, MSc*,
Martin B. Leon, MD*,4,
Jeffrey W. Moses, MD*,5,
Roxana Mehran, MD*,6 and
Gregg W. Stone, MD*,7,*
* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Cleveland Clinic, Cleveland, Ohio
Southampton University Hospital, Southampton, United Kingdom
San Raffaele Hospital, Milan, Italy
|| Helios Heart Center Siegburg, Siegburg, Germany
¶ Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts.
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Diabetes
Kaplan-Meier estimates representing the 4-year cumulative rates of death (top left), myocardial infarction (top right), protocol-defined stent thrombosis (bottom left), and target lesion revascularization (bottom right) for the pooled randomized trials of paclitaxel-eluting stents versus bare-metal stents in patients with diabetes mellitus. The number of patients at risk for each year is provided, equal to the number of patients with follow-up at each time period less those with earlier events.
|
|
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 No Diabetes
Kaplan-Meier estimates representing the 4-year cumulative rates of death (top left), myocardial infarction (top right), protocol-defined stent thrombosis (bottom left), and target lesion revascularization (bottom right) for the pooled randomized trials of paclitaxel-eluting stents versus bare-metal stents in patients without diabetes mellitus. The number of patients at risk for each year is provided, equal to the number of patients with follow-up at each time period less those with earlier events.
|
|
|
